The effect of insulin on circulating PCSK9 in postmenopausal obese women.

[1]  R. Kreis,et al.  Plasma PCSK9 concentrations during an oral fat load and after short term high-fat, high-fat high-protein and high-fructose diets , 2013, Nutrition & Metabolism.

[2]  A. Peterson,et al.  Furin-cleaved Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Is Active and Modulates Low Density Lipoprotein Receptor and Serum Cholesterol Levels , 2012, The Journal of Biological Chemistry.

[3]  A. Prat,et al.  Gene Inactivation of Proprotein Convertase Subtilisin/Kexin Type 9 Reduces Atherosclerosis in Mice , 2012, Circulation.

[4]  P. Ridker,et al.  Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial. , 2012, Clinical chemistry.

[5]  B. Dahlbäck,et al.  Relationship of plasma apolipoprotein M with proprotein convertase subtilisin-kexin type 9 levels in non-diabetic subjects. , 2011, Atherosclerosis.

[6]  R. Dullaart,et al.  Plasma proprotein convertase subtilisin-kexin type 9 does not change during 24h insulin infusion in healthy subjects and type 2 diabetic patients. , 2011, Atherosclerosis.

[7]  Tao Yang,et al.  Serum PCSK9 is associated with multiple metabolic factors in a large Han Chinese population. , 2010, Atherosclerosis.

[8]  J. Horton,et al.  Fasting reduces plasma proprotein convertase, subtilisin/kexin type 9 and cholesterol biosynthesis in humans , 2010, Journal of Lipid Research.

[9]  L. Bernier,et al.  A new method for measurement of total plasma PCSK9: clinical applications , 2010, Journal of Lipid Research.

[10]  E. Levy,et al.  Plasma PCSK9 is associated with age, sex, and multiple metabolic markers in a population-based sample of children and adolescents. , 2009, Clinical chemistry.

[11]  Jingwen Liu,et al.  Hepatocyte Nuclear Factor 1α Plays a Critical Role in PCSK9 Gene Transcription and Regulation by the Natural Hypocholesterolemic Compound Berberine* , 2009, The Journal of Biological Chemistry.

[12]  Jonathan C. Cohen,et al.  Genetic and metabolic determinants of plasma PCSK9 levels. , 2009, The Journal of clinical endocrinology and metabolism.

[13]  B. Angelin,et al.  Importance of proprotein convertase subtilisin/kexin type 9 in the hormonal and dietary regulation of rat liver low-density lipoprotein receptors. , 2009, Endocrinology.

[14]  E. Levy,et al.  Dichotomy between postprandial glucose and lipid profiles in adults with cystic fibrosis: a pilot study. , 2009, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[15]  Jonathan C. Cohen,et al.  Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor , 2008, Proceedings of the National Academy of Sciences.

[16]  D. Lopez,et al.  Diabetes alters LDL receptor and PCSK9 expression in rat liver. , 2008, Archives of biochemistry and biophysics.

[17]  J. Deisenhofer,et al.  Molecular basis for LDL receptor recognition by PCSK9 , 2008, Proceedings of the National Academy of Sciences.

[18]  K. Cianflone,et al.  Association of acylated ghrelin profiles with chronic inflammatory markers in overweight and obese postmenopausal women: a MONET study. , 2007, European journal of endocrinology.

[19]  Jonathan C. Cohen,et al.  Binding of Proprotein Convertase Subtilisin/Kexin Type 9 to Epidermal Growth Factor-like Repeat A of Low Density Lipoprotein Receptor Decreases Receptor Recycling and Increases Degradation* , 2007, Journal of Biological Chemistry.

[20]  Annik Prat,et al.  The Cellular Trafficking of the Secretory Proprotein Convertase PCSK9 and Its Dependence on the LDLR , 2007, Traffic.

[21]  Leiv Ose,et al.  Missense Mutations in the PCSK9 Gene Are Associated With Hypocholesterolemia and Possibly Increased Response to Statin Therapy , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[22]  Jonathan C. Cohen,et al.  Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. , 2006, The New England journal of medicine.

[23]  M. Krempf,et al.  Hepatic PCSK9 Expression Is Regulated by Nutritional Status via Insulin and Sterol Regulatory Element-binding Protein 1c* , 2006, Journal of Biological Chemistry.

[24]  C. Junien,et al.  Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia , 2005, Human mutation.

[25]  Alexander Pertsemlidis,et al.  Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9 , 2005, Nature Genetics.

[26]  Jay D. Horton,et al.  Post-transcriptional Regulation of Low Density Lipoprotein Receptor Protein by Proprotein Convertase Subtilisin/Kexin Type 9a in Mouse Liver* , 2004, Journal of Biological Chemistry.

[27]  A. Prat,et al.  NARC-1/PCSK9 and Its Natural Mutants , 2004, Journal of Biological Chemistry.

[28]  L. Bernier,et al.  Statins Upregulate PCSK9, the Gene Encoding the Proprotein Convertase Neural Apoptosis-Regulated Convertase-1 Implicated in Familial Hypercholesterolemia , 2004, Arteriosclerosis, thrombosis, and vascular biology.

[29]  J. Breslow,et al.  Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[30]  TP Leren,et al.  Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia , 2004, Clinical genetics.

[31]  Shwu‐Yuan Wu,et al.  SREBP-1c and Sp1 Interact to Regulate Transcription of the Gene for Phosphoenolpyruvate Carboxykinase (GTP) in the Liver* , 2004, Journal of Biological Chemistry.

[32]  R. Turner,et al.  Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.

[33]  M. Skolnick,et al.  A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree , 2004, Human Genetics.

[34]  Osama Hamdy,et al.  Evaluation of insulin sensitivity in clinical practice and in research settings. , 2003, Nutrition reviews.

[35]  J. Weissenbach,et al.  Mutations in PCSK9 cause autosomal dominant hypercholesterolemia , 2003, Nature Genetics.

[36]  S. Monier,et al.  Cell surface expression of LDL receptor is decreased in type 2 diabetic patients and is normalized by insulin therapy. , 2003, Diabetes care.

[37]  A. Prat,et al.  The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): Liver regeneration and neuronal differentiation , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[38]  R. DeFronzo,et al.  Glucose clamp technique: a method for quantifying insulin secretion and resistance. , 1979, The American journal of physiology.